LexaGene Receives 2021 BioTech Breakthrough Award
BEVERLY, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it was named the 2021 BioTech Breakthrough Molecular Diagnostics Solution of the Year.
The BioTech Breakthrough Award selection committee performs a comprehensive evaluation of life sciences and biotechnogly tools, services, and companies identifying innovative and standout technology that will improve the world. Award winners rise above their competitors and are considered stand out technology in a crowded market across many sectors. The program is open to all individuals or companies involved in producing publicly available products and services. Featured winners cross multiple categories, including but are not limited to biopharma, therapeutics, genomics, immunology, bioagriculture, and bioindustrial. Judges represented a mix of technology, business, academic, and marketing expertise within the industry.
Dr. Jack Regan, CEO and Founder of LexaGene stated, “We continue to make great strides in building our brand as we break through a crowded biotechnology market with our MiQLab™ System. This award is specifically focused on the concept of innovation, performance, functionality, value, and impact. I’m very proud of the strides we’ve made as we build a product that is like no other in the market. Our one-of-kind technology quickly and accurately diagnoses infections and detects drug resistance allowing for effective early treatment.”
He continued, “In just five short years, we’ve gone from a concept on paper to a commercialized product. Recognition like the one received from BioTech Breakthrough and the recently announced opportunity to be a Best in Show Spotlight company at the upcoming 47th Petcare Innovation Summit, reinforces to me, our Board, and our employees, that we have a cutting edge technology that will impact multiple markets.”
To learn more about LexaGene and the MiQLab System or subscribe to company updates, visit www.lexagene.com, or follow us on Twitter or LinkedIn.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing, and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Corporate & Media Contact: Gail Winslow Director of Marketing gwinslow@lexagene.com 978.482.6237 ir@lexagene.com 800.215.1824 Investors: Sharon Choe Vice President LaVoieHealthScience schoe@lavoiehealthscience.com (857) 241-7393
